Anemia drugs under scrutiny

Mar 13, 2008

U.S. drug regulators are contemplating further restrictions on the use of drugs to combat anemia in cancer patients.

A Food and Drug Administration advisory committee is to meet Thursday to consider eliminating the use of Amgen's drugs Epogen and Aranesp, and the Johnson & Johnson drug Procrit for cancer patients with certain types of tumors or eliminating the use among all cancer patients, The New York Times reported.

The newspaper said eight clinical trials have suggested the drugs might make tumors worse or shorten the life of cancer patients. One FDA adviser last year called the drugs "Miracle-Gro for cancer."

Researchers said the anemia drugs are synthetic forms of a human hormone called erythropoietin, or Epo, that is involved in the production of red blood cells. Epo may encourage the growth of blood vessels that nourish tumors or may actually stimulate tumors directly, scientists said. Another theory is that Epo protects tumors from being destroyed by chemotherapy.

Amgen said it has not seen any convincing evidence Epo does anything but spur red blood cell production, the newspaper said.

Copyright 2008 by United Press International

Explore further: FDA approves new drug for rare genetic disease

add to favorites email to friend print save as pdf

Related Stories

Drug for anemic cancer patients raises risk of death

Feb 26, 2008

Millions of cancer patients take drugs to boost their red blood cells and health when they become anemic after chemotherapy. But a new study by Northwestern University's Feinberg School of Medicine shows these drugs, called ...

Recommended for you

Boxed warnings are common in novel therapeutics

18 hours ago

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

19 hours ago

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

20 hours ago

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments : 0